Figure 6.

Compounds and antibodies affecting WNT/β-catenin-signaling pathway that were investigated in melanoma (preclinical studies, except for LGK974, which is tested in the clinical trial NCT01351103). APC—adenomatosis polyposis coli; AXIN—axis inhibition protein; BRG-1—brahma-related gene-1; BCL-9—B-cell CLL/lymphoma 9 protein; CBP—cAMP response element-binding protein; CK1α—casein kinase 1 α; CK1γ—casein kinase 1 γ; DKK1—Dickkopf-1; DVL—disheveled; ER—endoplasmic reticulum; FZD—frizzled; GSK3β—glycogen synthase kinase 3β; LRP5/6—lipoprotein receptor related protein 5/6; PYGO—pygopus; TKNS—tankyrase; β-TrCP—beta-transducin repeat–containing protein; Ub—ubiquitin.